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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
Rimonabant is a safe and effective treatment for patients with alcohol dependence.
Study Design: Systematic review of three English language randomized control trials published
in 2005, 2008 and 2010.
Data Sources: Three double-blind, placebo controlled randomized trials comparing Rimonabant
or Naltrexone to placebo were found using PubMed, OVID, Medline and Cochrane.
Outcomes Measured: Outcomes measured include event rate of heavy drinking days using the
timeline follow back method, which facilitates self-reporting of drinking habits by utilizing
calendars and personal recall. Other outcomes measured include the number of self-reported
drinks/day using daily call ins from study participants and number of days until first alcoholic
drink and number of days until first heavy drinking (as measured by timeline follow back
method).
Results: In a study by George et.al, there was no significant difference found in the number of
alcoholic drinks consumed by non-treatment seeking heavy alcohol drinkers when comparing the
Rimonabant and placebo groups during the 14 day study. A study by Soyka et.al. discovered that
participants treated with once daily Rimonabant showed a marked, but not statistically
significant, reduction in relapse to heavy drinking when compared to placebo after 12 weeks oif
treatment: 27.7% versus 35.6%, respectfully. Finally, another study included in this review
investigated the efficacy of intramuscular naltrexone as a treatment for alcohol dependence by
measuring the event rate of heavy drinking days. Results of this study showed that long-acting
IM naltrexone resulted in 25% reduction in heavy drinking days among treatment-seeking
alcohol dependent patients when compared to placebo. The compiled data also demonstrates that
both Rimonabant and Naltrexone are relatively safe to use in adult alcoholics, however patients
receiving Rimonabant were more likely to have treatment emergent adverse events such as
nausea, insomnia, headache, etc.
Conclusions: The results of two double-blind placebo controlled randomized control trials
showed no statistical treatment effect of Rimonabant versus placebo in reducing the number of
drinks per day, number of heavy drinking days, or time to heavy drinking relapse. Both
Naltrexone and Rimonabant are considered safe for use in adults, despite a modest amount of
mild adverse reactions associated with treatment.
Key Words: Rimonabant, Naltrexone, Alcohol dependence
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INTRODUCTION
Alcohol dependence is a serious medical health problem in the U.S., and has recently
become the 4th leading cause of disability in America5. Alcohol dependence, also known as
alcoholism, is a syndrome consisting of two phases: at risk drinking and alcohol addiction. At
risk drinking is typically defined as more than 4 drinks per day or 14 drinks per week for men
and more than 3 drinks per day or 7 drinks per week for women4. People affected by alcoholism
often show evidence of withdrawal when intake is interrupted, tolerance to the effects of alcohol,
and evidence of alcohol-associated illnesses such and alcoholic liver disease and cerebellar
degeneration10.
The lifetime risk for alcohol dependence in Western countries is 10-15% for men and 58% for women10. Alcoholism may contribute to more than 80,000 preventable deaths per year
and is responsible for 2.3 million years of potential life lost annually1. About 80% of people in
Western countries have consumed ethanol, and two-thirds admit to being drunk in the past year,
demonstrating how large of a demographic is at risk for alcoholism10. With this knowledge, it is
imperative for the physician assistant to have a low threshold of suspicion for alcohol abuse or
dependency in any person with a history of drug or alcohol consumption or clinical
manifestations of acute or chronic intoxication.
In 2006, the overall cost to the United States for alcohol-related health problems was
estimated to be $223.5 billion1. In 2006, there were more than 1.2 million emergency room visits
and more than 2.7 million physician office visits for alcohol-related conditions1. Life span is
decreased by 10 years in an alcoholic, with death most commonly resulting from heart disease,
cancer, automobile accidents and suicide10.
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Alcohol dependence is a chronic disease that typically presents with a craving for alcohol
and the inability to limit one’s intake of alcoholonitnued use of alcohol despite negative social,
physical and interpersonal problems or developmental of alcohol-related illnesses4. Potential
health complications of alcoholism include cardiomyopathy, cerebellar degeneration, peripheral
neuropathies, cirrhosis of the liver, esophageal varices, hormonal and nutritional deficiencies,
coagulation defects, pancreatitis, depression, psychological disease, cancer and fetal alcohol
syndrome in babies of alcoholic mothers4,10. Acute alcohol intoxication produces CNS
depression, manifesting as drowsiness, psychomotor dysfunction, lack of inhibition, dysarthria,
ataxia and nystagmus. Blood alcohol levels below 50 mg/dL rarely cause significant motor
dysfunction, while alcohol ingestion coupled with nausea and vomiting suggest blood alcohol
levels > 150 mg/dL4.
Alcohol dependence is diagnosed clinically by the DSM-IV as repeated alcohol related
difficulties in at least three of seven life areas over a 12 month period. Tolerance and withdrawal
symptoms are associated with more severe dependence. Some lab values may aid in the
diagnosis, including elevated liver enzymes, GTT> 35U, CDT > 20 U/L, high MCV (>91 um3)
and high serum uric acid (>416 mol/L)10. Questionnaires and interviewing methods such as the
CAGE questions and the AUDIT (The Alcohol Use Disorders Test) are a valuable tool for
identifying those patients with alcohol abuse or dependence4.
Cognitive behavioral therapy with an emphasis on motivational interviewing is the
primary intervention for alcoholism. Goals of CBT include emphasizing the positive actions that
the patient can take to reduce their alcohol consumption, reducing any “enabling” behavior of a
spouse or significant people, and facing denial. Rehabilitation, counseling and self-help groups

S. Hughes, Rimonabant and Alcohol Dependence, Page 5
such as Alcoholics Anonymous are an integral component of successful treatment. After
completing rehabilitation and CBT, over 60% of alcoholics remain sober for at least 1 year10.
Medical therapies are available for the treatment of alcoholism and include Disulfiram,
Acamprosate, and Naltrexone. Disulfiram, an ALDH inhibitor, produces symptoms of nausea
and vomiting with rising levels of acetaldehyde (breakdown product of ethanol) in the blood10.
This reaction may be dangerous for patients with heart disease, DM or stroke. Acamprosate has
modest effects on alcohol intake and functions by inhibiting NMDA receptors, resulting in a
decrease in the pleasurable side effects of ethanol ingestion. Naltrexone, an opioid receptor
antagonist, appears to shorten relapses, especially in patients with a specific mu-receptor
polymorphism4,10. Studies have suggested that use of Acamoprosate and Naltrexone in
combination is more efficacious than use alone10.
The CB1 cannabinoid receptor and mu-opioid receptors have been shown to have a
similar distribution in the brain, specifically sharing the same pre-synaptic nerve terminals and
signaling through a common receptor mediated G-protein coupled pathway7. Naltrexone, a mu
receptor blocker, is currently the first-line medical therapy for alcohol dependence. Animal
studies have shown that CB1 knockout mice had reduced voluntary alcohol consumption and
increased alcohol sensitivity2. Based on the success of Naltrexone combined with the positive
treatment response in animal studies, there is sufficient data to suggest that a CB1 cannabinoid
receptor antagonist such as Rimonabant may have a similarly therapeutic response in treating
alcoholism.
OBJECTIVE
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The objective of this selective EBM review is to determine whether or not Rimonabant
(Acomplia) is a safe and effective treatment for patients with alcohol dependence.
METHODS
Specific selection of three double-blind, placebo controlled randomized control trials
(RCT) were used for this review. The chosen population included adults > 18 years old with a
diagnosis of alcohol dependence or abuse. Interventions studied included Rimonabant 20 mg PO
QD and Naltrexone 380 mg IM and 190 mg IM. Comparisons were made between treatment
groups receiving Rimonabant or Naltrexone versus a placebo. Outcomes measures include event
rate of heavy drinking (>5 standard drinks/day for men, >4 standard drinks/day for women),
number of drinks per day, time to drinking and time to heavy drinking relapse (in days). All
outcomes were measured using patient self-reporting via call-ins or the timeline follow-back
method (based on calendars and personal recall). Safety associated and tolerability of
Rimonabant and Naltrexone were measured on the basis of adverse events (AE) and serious
adverse events (SAE).
Over the time period of November 2011-January 2012 the author accessed PubMed,
Medline, OVID and Cochrane Systemic Reviews using the key words “Rimonabant”, “Alcohol
dependence”, “alcohol” and “Naltrexone” to search for relevant RCTs. While searching for
articles inclusion criteria included: English language, human adult participants, articles published
within the past 10 years, peer-reviewed journals, randomized control trials and relevance to my
clinical question. All outcomes investigated are based on outcomes that are important to patients
(POEMs). Exclusion criteria can be found in Table 1. The statistics included in the data analysis
include NNT, NNH, p-values, hazard ratios and F-score.
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Table 1- Demographics and Characteristics of Included Studies
Study
Garbutt
(2005)5

Type
Double
Blind
RCT

# pts
624

Age
45 ± 10
years

George
(2010)6

Double
Blind
RCT

39

32 ± 2
years

Soyka
(2008)11

Double
Blind
RCT

253

44.8 ±
8.8 years

Inclusion Criteria
>18 y/o with
current DSMIVdiagnosis of
alcohol dependence
with a minimum of
2 episodes of heavy
drinking in 30 days
prior to study
Age 21-45 who
consumed 20-50
drinks/week with a
BMI of 18-30,
taking no other
medications and
tested negative for
HIV and hepatitis
with normal 12lead EKG

Exclusion Criteria
Evidence of liver
failure, current
diagnosis major
psychiatric illness,
dependence on
drugs, previous
inpatient treatment
for substance abuse
Major psychiatric
illness, history of
withdrawal
symptoms, not
currently seeking
treatment for
alcohol
consumption

W/D
3*

Interventions
Naltrexone
380 mg or 190
mg IM gluteal
injection q 4
weeks x 24
weeks

0

20 mg of
Rimonabant
PO QD x 14
days

Age 18-65 with
DSM –IV
diagnosis of
alcohol dependence
who are detoxified
from alcohol for 728 days prior to
randomization
without withdrawal
symptoms

Symptoms of
alcohol withdrawal
or drinking alcohol
in 3 days prior to
study. History of
WK syndrome,
withdrawal
seizures, delirium,
cirrhosis, or
alcohol-induced
psychosis. Pending
legal charges, IQ <
80, major
psychiatric illness

80

20 mg of
Rimonabant
PO QD x 12
weeks

*Although 246 participants dropped out of this trial, all patients who received at least 1 injection
of the long acting naltrexone were included in the final data analysis (624 people).
OUTCOMES MEASURED
The outcomes measured were based on actual patient self-reports. Event rate of heavy
drinking was measured by taking the number of heavy drinking days divided by the number of
days at risk for heavy drinking. Heavy drinking is considered to be intake of > 5 standardized
drinks/day for men or > 4 standardized drinks/day for women5. Another outcome measured the
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amount of daily alcoholic beverages consumed by daily patient call in, in an effort to capture the
patient’s consumption in their natural home setting6. The last outcomes were measured by
quantifying the number of days before a patient relapsed (based on reported drinking status,
Timeline Followback report of alcohol consumption, ethanol breath testing, plasma GGT level
and CDT value). The time until relapse to first period of heavy drinking was also investigated11.
Drinking status was assessed using the Timeline Followback method and the OCDS (Obsessive
Compulsive Drinking Scale) at every visit.
RESULTS
Two of the randomized control trials in this systematic review compared treatment with
oral Rimonabant to placebo, while another RCT compared treatment with intramuscular longacting Naltrexone to intramuscular placebo of the same volume.
The article by Soyka et.al was a 12 week study assessing the efficacy of Rimonabant 20
mg/day given in two 10 mg oral doses in the prevention of relapse to alcohol consumption in
recently detoxified alcoholics. Of the 260 patients who began the study, only 71.8% of the
participants in the Rimonabant group completed therapy while only 62% of participants in the
placebo group completed therapy11. All dropout patients were considered to have relapsed using
the Fischer exact test in one of the sensitivity analyses. The primary outcomes of this study
included time to relapse and time to heavy drinking relapse. The time to relapse of drinking and
heavy drinking (in days) was increased in the group receiving Rimonabant when compared to
placebo, however no statistically significant difference was found between the treatment groups.
The number needed to treat (NNT) value for relapse to heavy drinking in this study is 10,
meaning that ten patients would need to be treated with Rimonabant to prevent one patient from
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relapsing to heavy drinking. The p-values are not significant (see Table 3), and the odds ratio is
very close to 1 in both drinking relapse and heavy drinking relapse, showing that the treatment
effect was small. Patients taking placebo relapsed to heavy drinking 22 days before patients
taking Rimonabant.
Table 2. Primary Outcomes: Time to Relapse and Relapse Rates11

Drinking

Heavy
Drinking

Non-relapse Patients
Relapse Patients
Time to Relapse
Non-relapse Patients
Relapse Patients
Time to Relapse

Placebo (n=124)
50 (40.3%)
57 (46.0%)
24 days
58 (47.2%)
40 (32.5%)
52 days

Rimonabant 20 mg (n=129)
60 (46.5%)
53 (41.1%)
33 days
71 (57.7%)
32 (26.0%)
74 days

Table 3. Calculations for efficacy of relapse prevention11

Relapse to
Drinking
Relapse to Heavy
Drinking

Relative Risk
Reduction
(RRR)

Absolute Risk
Reduction
(ARR)

Number Needed
to Treat (NNT)

Odds Ratio

P-value
(< 0.05 is
significant)

15%

6%

16

0.77

0.375

22%

11%

10

0.65

0.125

The study by George, et. al. was a 2 week double-blind study with 49 non-treatment
seeking adult heavy alcohol drinkers who were randomly given either oral Rimonabant 20
mg/day or placebo. The data showed that there was no significant treatment effect between the
Rimonabant and placebo groups. The data uncovered in this study is represented in a continuous
manner and could not be converted to dichotomous data; there for RRR, ARR and NNT cannot
be calculated. The treatment effect (number of drinks/day) is described by an F-score of F(1,36)=
0.05 and a p-value of p=0.836. Based on these values, the author determined that the treatment
effect was small and of no statistical significance.
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The study by Garbutt, et al. was a 6-month, randomized, double-blind placebo controlled
trial investigating the event rate of heavy drinking days after treatment with long-acting
intramuscular Naltrexone versus placebo in 627 actively alcohol-dependent adults. Although
only 378 participants actually finished the 6-month trial, all patients who received at least 1
injection of Naltrexone were included in the final data analysis (624 participants)5. The data
showed that participants taking 380 mg IM naltrexone had a 25% reduction in the event rate of
heavy drinking when compared to placebo (p=0.03)5. This p-value is <0.05, showing that there
was a statistically significant decrease in the rate of heavy drinking days between the treatment
groups. Male patients and patients without lead in drinking taking Rimonabant had an even more
significant reduction in the rate of heavy drinking, 44% and 80% respectively. Since the data is
represented in hazard ratios and no specific data points are given, data is continuous and ABI,
RBI and NNT cannot be calculated.
Table 4. Analysis of Outcomes for article by Garbutt et.al.

Heavy
Drinking
Female
Male
Lead in
drinking
No lead in
drinking

Population
624

Naltrexone 380 mg v. Placebo
Hazard Ratio*
P-value
0.75 (0.60-0.94)
0.03

Naltrexone 190 mg v Placebo
Hazard Ratio
P-value
0.83 (0.68-1.02)
0.07

201
423
571

1.23 (0.85-1.78)
0.56 (0.41-0.77)
0.79 (0.62-1.00)

0.28
<0.001
0.05

1.07 (0.73-1.58)
0.83 (0.64-1.07)
0.93 (0.75-1.12)

0.72
0.16
0.48

53

0.20 (0.07-0.62)

0.005

0.05 (0.02-0.15)

<0.001

*Hazard ratio is an estimate of treatment effect size for each individual treatment relative to placebo and should be
interpreted as follow: HR = 1 indicates no treatment effect, HR = 0.75 is a 25% reduction in heavy drinking relative
to placebo, HR = 1.25 is a 25% increase in heavy drinking relative to placebo, etc.

SAFETY
Based on data compiled by Soyka et al, Rimonabant 20 mg/day resulted in a NNH of 23,
meaning that 23 patients must be treated for one patient to experience a treatment emergent
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adverse event. NNH for serious adverse events was -38, meaning that thirty eight people would
have to be treated with Rimonabant for one less serious adverse event to occur versus placebo.
Of note, three suicide attempts occurred in the placebo group compared to 1 attempted suicide in
the Rimonabant group. No deaths occurred during the study period.
Garbutt and colleagues found that 7.2% of patients in the placebo group discontinued
therapy secondary to a serious adverse event compared to 5.4% of patients in the Naltrexone 380
mg group. The participants treated with Naltrexone were two times as likely to have an adverse
event compared to those taking placebo. For every 14 people treated with Naltrexone 380 mg IM
one more patient experienced an adverse treatment reaction. As for serious adverse events such
as hospitalization or pneumonia, 55 patients would need to be treated with Naltrexone 380 mg
IM to experience one less serious adverse event when compared to placebo.
The study by George et al cited no specific adverse drug reactions, however the author
states that no significant differences for drug side effects were found using a Visual Analog
Scale to monitor patients at every clinical visit. No participants reported feelings of depression of
suicidal ideation.
Table 5. Safety and tolerability of Rimonabant and Naltrexone

Soyka,
et.al.11

Medication
regimen of
interest

Most common adverse side
affects

Placebo
(%)

Treatment
(%)

Serious adverse events:
hospitalization due to
alcoholism and suicide
attempts.

11.8%

9.2%

Number
needed to
harm
(NNH)
-38

Rimonabant 20
mg/day

Treatment Emergent
Adverse Events:
Headache, Alcoholism,
Diarrhea, Fatigue, Nausea,
Insomnia, Anxiety,
Hypertension, Asthenia,

48.8%

53.3%

23
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Depression
George,
et.al.6
Garbutt,
et.al.5

Rimonabant 20
mg/day
Naltrexone 380 mg
IM
injection/month

No adverse reactions reported

N/A

N/A

N/A

SAE: Hospitalization for
alcohol detoxification,
pneumonia
AE: Nausea, headache,
fatigue, insomnia, vomiting,
decreased appetite, diarrhea

7.2%

5.4%

-55

6.7%

14.1%

14

DISCUSSION
The endocannabinoid and opioid neural signaling pathways have both been implicated in
the development and maintenance of alcohol dependence and abuse disorders. The opioid
signaling pathways have already been utilized clinically with the introduction of Naltrexone, an
opioid mu-receptor antagonist which has been FDA approved for the treatment of alcohol
dependence. Rimonabant, a CB1 endocannabinoid receptor antagonist, acts on a pathway with a
very similar mechanism of action in the brain as the opioid signaling pathways7, leading clinical
scientists to investigate the efficacy of Rimonabant as a treatment for alcohol dependence, based
on the relative success of Naltrexone. Although animal studies were encouraging and showed a
significant positive treatment effect with Rimonabant2, the human RCTs discussed in this
systematic review show no significant treatment effect between Rimonabant and placebo.
Although Soyka et al found a 11% absolute risk reduction of heavy drinking in participants
taking Rimonabant, these results were not found to be significant.
Limitations to this systematic review were numerous. The study by George et al
investigated a very small population size (n=49) and treated the participants for a duration of
only two weeks6. Of the two studies investigating Rimonabant vs. placebo, the treatment groups
varied significantly: one population included recently detoxified alcohol dependent patients
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while the other included non-treatment seeking alcoholics. The obvious contrast in the
population’s willingness and initiative to obtain treatment for alcoholism may substantially
confound the medication treatment effects.
Only two placebo-controlled randomized control trials are currently in circulation
investigating the use of Rimonabant for the treatment of alcohol abuse disorders in humans.
Reasons for the lack of RCTs may include the numerous treatment options that are already
available for alcohol dependence, the serious side effects discovered from administration of
Rimonabant in 2007 by the FDA, including increased risk of suicidal ideation (OR=1.9)3 and
severe depression (OR=2.5)3, and the lack of FDA approval for the drug Rimonabant. For these
reasons, coupled with the lack of significant treatment effect found in two randomized control
trials by Soyka and George, the author believes that future research into this therapeutic option
should be limited until a more thorough investigation into the drug safety has been concluded
and FDA approval has been obtained.
CONCLUSIONS
Rimonabant (Acomplia) is a safe treatment for alcohol dependence based on the
information reported in this systematic review. However, based on previous reports of suicidal
ideation and severe depression in patients taking Rimonabant, the safety profile for this drug
requires serious consideration and further study. Effectiveness as evidenced by increased days to
first relapse and reduced risk of relapse to drinking and heavy drinking were seen, however no
statistically significant differences were found when comparing treatment with Rimonabant to
placebo. Future research is warranted to evaluate treatment with a peripherally acting neutral
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CB1 antagonist8 in a sufficiently large population of alcohol dependent adults who are seeking
treatment and have already begun cognitive behavioral therapy.
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